Regulation of Human Epidermal Melanocyte Biology By β-Endorphin  by Kauser, Söbia et al.
ORIGINAL ARTICLE
See related Commentary on page xii
Regulation of Human Epidermal Melanocyte Biology
By b-Endorphin
S˛bia Kauser, Karin U. Schallreuter, Anthony J. Thody, Christopher Gummer,n and Desmond J. Tobin
Department of Biomedical Sciences, University of Bradford,WestYorkshire, UK; nProcter and Gamble Ltd, Surrey, UK
b-Endorphin is an opioid peptide cleaved from the
precursor pro-hormone pro-opiomelanocortin, from
which other peptides such as adrenocorticotropic
hormone, b-lipotropic hormone, and a-melanocyte-
stimulating hormone are also derived. a-Melanocyte-
stimulating hormone and adrenocorticotropic hormone
are well documented to regulate human skin pigmenta-
tion via action at the melanocortin-1 receptor.Whereas
plasma b-endorphin is reported to increase after expo-
sure to ultraviolet radiation, to date a functional role for
b-endorphin in the regulation of human epidermal
melanocyte biology has not been demonstrated. This
study was designed to examine the involvement of
the b-endorphin/l-opiate receptor system in human
epidermal melanocytes.To address this question we em-
ployed reverse transcription^polymerase chain reaction,
and immunohistochemistry/cytochemistry and immu-
noelectron microscopy using b-endorphin and l-opiate
receptor speci¢c antibodies. A functional role for b-en-
dorphin was assessed in epidermal melanocyte cultures
by direct stimulation with the peptide. This study dem-
onstrated the expression of l-opiate receptor mRNA in
cultured epidermal melanocytes, as well as mRNA for
pro-opiomelanocortin. In addition, we have shown that
b-endorphin and l-opiate receptor are expressed at the
protein level in situ in glycoprotein100-positive melano-
cytes. The expression of both b-endorphin and l-opiate
receptor correlated positively with their di¡erentiation
status in vitro. Furthermore, immunoelectron micro-
scopy studies revealed an association of b-endorphin
with melanosomes. Functional studies showed that
b-endorphin has potent melanogenic, mitogenic, and
dendritogenic e¡ects in cultured epidermal melano-
cytes deprived of any exogenous supply of pro-opio-
melanocortin peptides. Thus, we report that human
epidermal melanocytes express a fully functioning b-
endorphin/l-opiate receptor system. In the absence of
any data showing cross-talk between the l-opiate re-
ceptor and the melanocortin-1 receptor, we conclude
that the b-endorphin/l-opiate receptor system partici-
pates in the regulation of skin pigmentation. Key words:
l-opiate receptor/dendricity/melanogenesis/proopiomelanocortin/
skin. J Invest Dermatol 120:1073 ^1080, 2003
b-Endorphin (b-END) is a cleavage product of the precursor
pro-hormone pro-opiomelanocortin (POMC). Other peptides,
including adrenocorticotropic hormone (ACTH), a-melanocyte-
stimulating hormone (a-MSH), and b-lipotropic hormone (b-
LPH) are also produced from POMC by the actions of the
pro-hormone convertases 1 and 2 (Benjannet et al, 1991; Seidah
et al, 1994). It is now well established that the skin is also a local
source and target for POMC-derived peptides (Thody et al, 1983;
Slominski et al, 1993; Wintzen and Gilchrest, 1996). a-MSH and
ACTH have been well documented to regulate human skin pig-
mentation via action at the melanocortin-1 receptor (MC-1R)
(Lerner and McGuire, 1964; Hunt et al, 1994a, b, c; Suzuki et al,
1996;Wakamatsu et al, 1997).
b-END is an opioid peptide representing the 61^91 amino acid
sequence of b-LPH (Dalayeun et al, 1993). Opioids exert their
biologic e¡ects by activating membrane-bound receptors, which
consist of three major classes mu (m), delta (d), and kappa (k)
(Pasternak, 1993). b-END binds with high a⁄nity to m and d opi-
ate receptors (Gilmore and Weiner, 1989). b-END and other
opioids, such as the enkephalins and dynorphins, mediate their
biologic actions by inhibition of the adenylate cyclase pathway
and a decrease in the formation of intracellular cyclic adenosine
monophosphate (Kie¡er, 1995).
Elevated plasma b-END levels have been reported in derma-
toses, including psoriasis (Glinski et al, 1994), atopic dermatitis
(Glinski et al, 1995), and the pigmentation disorder vitiligo
(Mozzanica et al, 1992; Caixia et al, 2001). The onset of these con-
ditions can be triggered or their course can be aggravated by psy-
chologic stress (Seville, 1989), thus implicating the involvement of
classical stress hormones such as the endorphins in these disorders.
Moreover, increased plasma b-END and b-LPH levels post-ultra-
violet (UV)A exposure have been associated with the observed
increase in skin pigmentation in humans (Levins et al, 1983); how-
ever, more recent studies have reported that plasma b-END levels
do not rise after single or repeated exposure to UVA, UVA-1, or
UVB radiation (Wintzen et al, 2001).
ACTH, a-MSH (Schauer et al, 1994), and b-END (Wintzen
et al, 1996) are produced by human epidermal keratinocytes (EK)
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in vitro and their production is upregulated in response to UVB
radiation. In addition, the presence of b-END, a-MSH, andACTH
has also been identi¢ed in normal and malignant human melano-
cytes in vitro (Slominski, 1998), as well as in human skin (Slominski
et al, 2000b). The expression of b-END and other POMC pep-
tides has been demonstrated in normal and pathologic skin, and
was elevated under pathologic conditions but also during healing
and regeneration (Slominski et al, 1993; Nagahama et al, 1998).
Recent data indicate that the human epidermis expresses a
functionally active b-END receptor. Both m-opiate receptor
mRNA and protein expression have been found in human epi-
dermis (Bigliardi et al, 1998). b-END is a speci¢c agonist at the
m-opiate receptor in human skin; receptor expression was down-
regulated by b-END and this was reversed with an anti-m-opiate
receptor antibody or the antagonist naloxone. Notably, b-END
was also shown to upregulate the expression of cytokeratin 16, a
marker for keratinocyte di¡erentiation (Bigliardi-Qi et al, 2000).
Whereas a-MSH and ACTH has been shown to regulate hu-
man skin pigmentation (Lerner and McGuire, 1964; Hunt et al,
1994a, b, c; Suzuki et al, 1996;Wakamatsu et al, 1997). These studies
have led to an MC-1R-centric view of the regulation of mamma-
lian melanogenesis; however, b-LPH, the immediate precursor
of b-END, stimulates melanogenesis in amphibians and in sheep
(Lohmar and Li, 1968). Moreover, elevated serum levels of b-LPH
have been associated with generalized hyperpigmentation in
humans (Al Rustom et al, 1986). Despite these tentative clues,
however, a functional role for b-END in the regulation of human
skin pigmentation has not yet been demonstrated.
This study examines the b-END/m-opiate receptor system in
epidermal melanocyte (EM) biology and presents evidence that
b-END is a potent melanocyte modi¢er by upregulating mela-
nocyte proliferation, dendricity, and melanogenesis.
MATERIALS AND METHODS
Cell culture
EM EM cultures were established from normal human haired scalp tis-
sue, obtained with informed consent after elective plastic surgery, from
eight females (age range 43^62 y, mean age 52 y, photo skin type III^V,
Fitzpatrick classi¢cation; Fitzpatrick et al, 1974). This study was conducted
with Local Human Ethics Committee approval. All cell culture reagents
were obtained from Invitrogen Ltd (Paisley, U.K.) unless otherwise stated.
The skin samples were collected in RPMI 1640 medium supplemented
with 10% fetal bovine serum, 12.5 mg fungizone per ml, 500 units per ml
penicillin, and 500 mg streptomycin per ml, and were processed within 5 h
of surgery.
Brie£y, tissue specimens were washed with 0.1 M phosphate-bu¡ered sal-
ine (PBS) pH 7.4 containing 12.5 mg fungizone per ml, 500 units per ml
penicillin, and 500 mg streptomycin per ml. Epidermal sheets were sepa-
rated from the underlying dermis after an 18 h incubation in 0.25% trypsin
solution at 41C and placed in T25 cell culture £asks (Corning Costar Cor-
poration, Cambridge, MA) containing Eagle’s minimal essential medium
(EMEM) supplemented 2% FBS, 1  concentrated nonessential amino
acid mixture, antibiotics, 2 mM L-glutamine, 5 ng basic ¢broblast growth
factor per ml, and 5 ng endothelin-1 per ml (Sigma, Poole, Dorset, U.K.).
Residual epidermal material was carefully removed and the medium was
replenished after 48 h. Cells were incubated at 371C in a 5% CO2
atmosphere and fed every third day.
EK These were established by selectively trypsinizing EM from the co-
culture at the primary culture stage, using 0.05% trypsin and 0.53 mM ethy-
lenediamine tetraacetic acid solution. The detached EM were transferred
into a separate culture dish, the remaining EKwere then switched to kera-
tinocyte serum free medium.
Isolation of RNA EM and EK were maintained in culture media
without FBS or bovine pituitary extract (BPE) 48 h prior to all
experiments. This treatment removes all exogenous sources of POMC
peptides, as the half-lives of a-MSH, ACTH (Eberle, 1988), and b-END
(Morch and Pedersen, 1995) are less than 60 min. Total RNAwas isolated
from detached EM and EK by the guanidinium thiocyanate^phenol^
chloroform-based method, using Tri-Reagentt (Sigma, Dorset, U.K.)
according to the manufacturer’s instructions. Total RNA was isolated
from the aqueous phase and the resulting RNA pellet was dissolved in
nuclease-free water (Sigma, Dorset, U.K.). Total RNA isolated from EM
was then puri¢ed using a Dynabeads mRNA direct kit (Dynal AS, Oslo,
Norway) according to the manufacturer’s instructions. This additional
puri¢cation step was necessary to remove traces of melanin, which can be
inhibitory to the polymerase chain reaction (PCR). (Eckhart et al, 2000).
To avoid possible contamination of genomic DNA, extracted total RNA
samples were additionally treated with deoxyribonuclease I, ampli¢cation
grade (Invitrogen Ltd) according to the manufacturer’s instructions.
Reverse transcriptase^PCR The synthesis of cDNA was performed
using RevertAidTM M-MuLV Reverse Transcriptase (MBI Fermentas,
Vilnius, Lithuania) according to the manufacturer’s instructions using 2 mg
of total RNA or 0.2 mg of mRNA and oligo(dT)18 and random hexamer
primers (Sigma Genosys, Pampisford, Cambridgeshire, U.K.). All PCR
reagents were obtained from MBI Fermentas, unless otherwise stated.
One microliter of cDNA was used in the PCR ampli¢cation in a
50 ml reaction mixture containing the following components: 1PCR
bu¡er [75 mM Tris^HCl pH 8.8, 20 mM (NH4)2SO4, 0.01% Tween 20],
1.0 or 2.5 mM MgCl2 for POMC and m-opiate receptor-speci¢c pri-
mers, respectively, 20 pmol of each primer (Sigma Genosys), 0.2 mM
deoxyribonucleoside triphosphate mix, 1.0 unit of Taq DNA polymerase,
and, ¢nally, nuclease-free water (Sigma, Dorset, U.K.) was added to make
a ¢nal reaction volume of 50 ml. POMCwas ampli¢ed using primer sets as
previously described by Slominski et al (1995) and a modi¢ed protocol with
one cycle at 941C for 5 min, 35 cycles at 941C for 1 min, 671C for 1 min,
721C for 1 min, and a ¢nal cycle at 941C for 1 min, 671C for 1 min, 721C
for 10 min. Plasmid containing POMC gene (gift from Dr J. Ancans,
University of Riga, Latvia) was used as a positive control for POMC
mRNA expression. m-Opiate receptor was ampli¢ed using primers sets
and PCR parameters as described by Bigliardi et al (1998). EK were used
as a positive control cell line for m-opiate receptor mRNA expression.
RNA samples that were not reverse transcribed and the omission of
cDNA from the reaction mixture served as negative controls.
Ampli¢cations were performed using the Hybaid PCR sprint
temperature cycling system (Hybaid, Ashford, Middlesex, U.K.). After
ampli¢cation, 10 ml of the reaction mixture was mixed with 4 ml gel
loading solution (MBI Fermentas) and loaded directly on to 1.5% agarose
gel (Sigma, Dorset, UK) containing 1 mg per ml of ethidium bromide
(Sigma, Dorset, UK). A 100 bp DNA ladder (New England Biolabs,
Hitchin, Hertfordshire, U.K.) was also loaded followed by electrophoresis
at a constant voltage of 100 V using 0.5Tris-borate bu¡er. Gels were
photo-documented using the UVitec gel documentation system (UVitec
Limited, Cambridge, U.K.).
Immunohistochemistry Normal human haired scalp tissue was
obtained after elective plastic surgery (from ¢ve females, age range 43^60
y, mean age 50 y) or from occipital scalp tissue of two normal healthy
males (age 23 and 36 y). The tissue was cut into approximately 0.4 cm2
segments and was mounted using OCTt embedding medium (Raymond
A. Lamb, Eastbourne, East Sussex, U.K.). Seven micrometer thick
cryosections were cut on to poly L-lysine coated slides. The slides were
air-dried at room temperature for 1 h and then ¢xed in ice cold acetone
for 10 min at 201C and subsequently rehydrated in PBS for 5 min.
Sections were blocked in 10% normal donkey serum in PBS for 90 min at
room temperature and then rinsed brie£y in PBS. This was followed by
incubation with the ¢rst primary monoclonal antibody b-END 1 : 10
(Biogenesis, Poole, Dorset, UK) or m-opiate receptor 1 : 100 (Gramsch
Laboratories, Schwabhausen, Germany) in 1% normal donkey serum in
PBS at 41C for 18 h. After incubation the antibodies were carefully
aspirated and the sections were washed four times in PBS for 20 min
followed by a ¢nal rinse in distilled water. The sections were then
incubated with a rhodamine-conjugated donkey anti-rabbit or anti-mouse
secondary antibody (Jackson Immunoresearch Laboratories, Inc., West
Grave, Pennsylvania, USA). The secondary antibodies were used at a 1 : 50
dilution and incubated for 60 min at room temperature, followed by four
washes in PBS. For the detection of the second marker the sections were
further blocked with 10% normal donkey serum, covered and incubated for
90 min at room temperature. After a brief rinse in PBS they were incubated
with the second primary antibody, NKI/beteb 1 : 30 (Monosan, Uden, the
Netherlands), a melanocyte lineage-speci¢c marker against glycoprotein100
for 2 h at room temperature, followed by subsequent washing steps.
The sections were then incubated with a £uorescein-conjugated donkey
anti-mouse secondary antibody (Jackson Immunoresearch Laboratories,
Inc.) for 60 min at room temperature. The sections were washed in PBS
as previously described, rinsed in distilled water, carefully blotted dry
and then mounted inVectashield mounting medium with 40,6-diamidino-
2-phenylindole (Vector Laboratories Ltd, Peterborough, U.K.). The
omission of both primary antibodies, but the inclusion of secondary
antibodies, served as negative controls.
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The resulting staining was visualized with a Leica DMIRB/E £uorescence
microscope (Leica,Wetzlar, Ossett, Germany) and photo-documented with
the aid of a computer assisted 3-CCD color video camera (Optivision,
Ossett, West Yorkshire, U.K.) and the Image Grabber PCI graphics
program (Neotech Ltd, Easleeigh, Hampshire, U.K.). The images
produced with the two di¡erent £uorochromes rhodamine (red) and
£uorescein (green) were subsequently merged together using the Paint
Shop Prot 7 graphics program (JascSoftware, Banbury, Oxon, U.K.).
Co-localization of b-END and m-opiate receptor with gp100-positive
EM was indicated by the production of a yellow color.
Immunocytochemistry For staining of cultured EM and EK (passages
2^5), cells were seeded into eight-well Laboratory-Teks chamber slides
(ICN Biomedicals, Inc., Aurora, OH, USA) at a seeding density of 5000
cells per well and were grown for at least of 2^3 d. FBS and BPE were
omitted from the culture media 48 h prior to immunostaining. Cells were
rinsed brie£y in PBS for 5 min and then ¢xed in ice cold methanol for
10 min at ^ 201C and subsequently rehydrated in PBS for 5 min. Brie£y,
cells were blocked in 10% normal goat serum for 90 min at room
temperature, rinsed brie£y in PBS and incubated with either b-END 1 : 10
or m-opiate receptor 1 : 100 antibodies in 1% normal goat serum in PBS at
41C for 18 h. Subsequent steps in immunostaining were performed using
the DAKO LSABs2 HRP kit and DAKOAEC substrate system (DAKO,
Carpinteria, CA) according to the manufacturer’s instructions.
Assessment of melanin content, dendricity, and cell proliferation EM
(passages 2^5) were seeded at a density of 1  105 cells per T25 cell culture
£ask (Corning Costar Corporation, Cambridge, MA) and allowed to attach
overnight. Melanocyte cultures were grown without FBS and BPE for 48 h
prior to stimulation with 10^8 M b-END (Sigma, Dorset, U.K.) for 72 h.
Melanocytes from the same donor were maintained in parallel in the absence
of the peptide and served as a negative control. b-END (10^8 M) was chosen
for stimulation, as the greatest e¡ects on melanogenesis, dendricity, and
proliferation were seen at this concentration during preliminary experiments
compared with 10^6 M and 10^10 M. The testing of a broader range of b-END
concentrations was di⁄cult given the limitations of melanocyte number at
low passage.
For the assessment of melanocyte dendricity, cells were photographed 24
and 72 h after b-END stimulation. Representative photographs were taken
from seven to eight random and di¡erent ¢elds incorporating approximately
10 cells for each cell line. Changes in EM dendricity were assessed and
compared with controls. The cells were subsequently trypsinized and
counted using a Neubauer counting chamber. Melanocytes were then
pelleted by centrifugation and solubilized in up 0.5 ml of 1 M sodium
hydroxide, followed by boiling for 10 min. Melanin content was measured
spectrophotometrically at 475 nm. A standard curve of synthetic melanin
(Sigma, Dorset, U.K.) 0.05^100 mg per ml was used as a basis for the
determination of melanin content. Results were determined as picograms of
melanin per cell and expressed as percentage increase in melanin content above
control unstimulated cells. The increase in cell number was expressed as
percentage increase in cell number above control unstimulated levels.
Immunogold transmission electron microscopy EMwere established
from normal human scalp tissue. FBS and BPE were removed from the
culture medium 48 h prior to experiments. Melanocyte cultures (passages
3^5) were processed for immunoelectron microscopy as follows: cells were
trypsinized and then pelleted by gentle centrifugation. Cells were
subsequently ¢xed in 0.5% glutaraldehyde (Agar Scienti¢c, Stanstead,
Essex, U.K.) and 2% paraformaldehyde (Sigma, Dorset, U.K.) in 0.1 M
sodium cacodylate bu¡er (Sigma, Dorset, U.K.) containing 0.027 mM CaCl2
(Sigma, Dorset, U.K.) bu¡ered to pH 7.4 for 1 h at room temperature. After
¢xation cells were washed in PBS over 25 min, rinsed in 0.1 M glycine
(Sigma, Dorset, U.K.) in PBS for 5 min and then pelleted through 1% low
melting point agarose (Bio-Rad Laboratories, Hercules, CA) in PBS. The
cell/agar blocks were dehydrated in graded series of ethanol. Blocks were
in¢ltrated with hydrophillic Unicryl resin (British BioCell International,
Cardi¡,Wales, U.K.) followed by polymerization using UV light (360 nm)
of 2  8 W for 3 d at 41C.
Ultrathin sections (90 nm) were cut using a Reichert-Jung ultramicrotome
(Vienna, Austria), mounted on 200 mesh nickel grids coated with a carbon
¢lm (Agar Scienti¢c) and blocked in 10% normal goat serum and 2%
bovine serum albumin in PBS (pH 8.2) for 1 h. One percent normal goat
serum in the above blocking bu¡er was used to dilute both the primary
and secondary antibodies. The sections were then washed twice in PBS
containing 2% bovine serum albumin (pH 8.2) followed by incubation
with the primary antibodies b-END neat or m-opiate receptor 1 : 100 for
18 h at 41C. The sections were then washed in 2% bovine serum albumin
in PBS, and then incubated in 1 : 60 dilution of the secondary goat anti-
rabbit or anti-mouse antibody conjugated to 10 nm gold particles (British
BioCell International, Cardi¡ Wales, UK) for 1 h at room temperature and
then washed ¢nally in distilled water.
Sections were lightly counterstained with 2% uranyl acetate and Reynold’s
lead citrate solution, and examined and photographed using a JEM-1200 EX
transmission electron microscope (Jeol Tokyo, Japan).
Statistical analysis Statistical signi¢cance was assessed using Student’s
paired t test.
RESULTS
EM express l-opiate receptor and POMC mRNA in
vitro Reverse transcriptase^PCR with primers speci¢c for m-
opiate receptor produced ampli¢cation products of the expected
size of 433 bp in normal human EK and EM (Fig 1A). As b-
END is a cleavage product of POMC, the expression of the
POMC message was also analyzed in cultured EK and EM and
produced the expected 260 bp product speci¢c for exon 3 of the
POMC mRNA (Fig 1B). Ampli¢cation of RNA samples
that were not reverse transcribed and samples where cDNA had
been omitted from the reaction mixture were also subjected to
PCR. These negative controls did not reveal a speci¢c product
(Fig 1A, B). Thus, cultured EM express the mRNA for both
POMC and the m-opiate receptor.
EM express b-END and l-opiate receptor in situ The
expression of b-END protein was present throughout the
epidermis but was more prominent in di¡erentiated cells in the
spinous and granular layers compared with undi¡erentiated basal
cells. Individual dendritic cells in the basal layer of the epidermis
showed strong cytoplasmic b-END expression (Fig 2A). Double
immunolabeling with antibodies against gp100 and b-END
con¢rmed the melanocytic nature of these b-END-positive cells
(Fig 2C). The omission of both primary antibodies but inclusion
of secondary antibodies did not produce any speci¢c staining
(data not shown).
Cytoplasmic m-opiate receptor protein expression was observed
throughout the epidermis but here was stronger in the basal
layer of the epidermis (Fig 2D). Double immunolabeling with
m-opiate receptor and gp100 speci¢c antibodies revealed strong
colocalization of m-opiate receptor with gp100-positive EM
(Fig 2F). To assess which cell subpopulations in the epidermis
expressed both the m-opiate receptor and b-END, double
immunolabeling was used. Co-localization of m-opiate receptor
with b-END was prominent in the di¡erentiated cell layers
and also in individual cells located in the basal layer of the
epidermis. These cells showed an identical distribution pattern to
the gp100-positive cells (Fig 3C). Therefore, these results show
Figure1. Detection of l-opiate receptor and POMC-speci¢c tran-
scripts by reverse transcriptase^PCR in cultured EM and EK. Total
RNAwas isolated from cultured cells and ampli¢ed by reverse transcrip-
tion using m-opiate receptor and POMC-speci¢c primers followed by 1.5%
agarose gel electrophoresis. Detection of a 433 bp product speci¢c for m-
opiate receptor (A), detection of a 260 bp product speci¢c for POMC (B).
(A) Lane 1: DNA ladder; lane 2: EK; lane 3: EM; lane 4: negative control no.
1, omission of cDNA; lane 5: negative control no. 2, substitution of cDNA
with total RNA. (B) Lane 1: DNA ladder; lane 2: EK; lane 3: EM; lane 4:
plasmid containing POMC gene; lane 5: negative control no. 1, omission of
cDNA; lane 6: negative control no. 2, substitution of cDNA with total
RNA.
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that both b-END and m-opiate receptor colocalize with gp100-
positive EM in situ.
EM and keratinocytes express l-opiate receptor and b-END
in vitro Cultured EM exhibited a positive correlation between
level of b-END expression and di¡erentiation status, more di¡er-
entiated melanocytes (i.e., more dendritic and more pigmented)
showed stronger b-END immunoreactivity compared with less
di¡erentiated cells. Expression of b-END was present throughout
the cell body but was prominent in granular structures in the
perinuclear region of the cells and interestingly, also in the
nucleus (Fig 4A). Similarly, the expression of the m-opiate receptor
was also correlated with di¡erentiation status. Immunoreactivity
was observed throughout the cell body being strongest in more
di¡erentiated melanocytes and showed a rather di¡use granular
staining pattern. Strong expression was also seen on the cell
membrane (Fig 4B). The omission of the primary antibody did
not result in any staining (Fig 4C).
b-END was strongly expressed in the perinuclear region of
cultured EK and was more marked in di¡erentiated keratino-
cytes (Fig 4D). This result is in agreement with the in situ
¢ndings above, where strong immunoreactivity was observed
in the suprabasal layers of the epidermis. In contrast to EM,
granular staining was not observed in the EK nucleus.
Immunoreactivity for m-opiate receptor was also expressed in
cultured EK but in these cells was prominent in the perinuclear
region of cells with a basal cell phenotype (Fig 4E). No staining
was observed in the negative control where the primary antibody
had been omitted (Fig 4F). Thus, these in vitro results show
that both EM and EK express b-END and m-opiate receptor
protein.
b-END upregulates dendricity in EM in vitro In order
to assess the functional signi¢cance of m-opiate receptor and
b-END protein expression in EM both in situ and in vitro,
we determined the e¡ects of b-END stimulation on EM
morphology. Prior to b-END stimulation EM exhibited a
predominately bipolar morphology with occasional tripolar cells
(Fig 5A,C). Stimulation with b-END (10^8 M) induced cell
dendricity in all EM lines examined (n¼ 8). The e¡ect was
variable, with some cultures more responsive than others. The
extent of b-END stimulation of dendricity did not correlate
with di¡erent photo skin types (Fig 5B,D). Therefore, these
results show that exogenous b-END can signi¢cantly increase
dendricity in cultured EM.
b-END upregulates melanogenesis and proliferation in EM
in vitro Next we examined the e¡ect of b-END on melano-
genesis and proliferation. Stimulation of EM cultures derived
from photo skin types III^V (Fitzpatrick classi¢cation) with
b-END (10^8 M) signi¢cantly increased melanogenesis after 72 h
in all cell lines tested (n¼ 8; po0.001) (Fig 6A). The e¡ects
were variable in the cell lines examined and ranged from
13.2%73.14 (SEM) to 38.5%73.14 with an average increase of
23.6%73.14 above control unstimulated levels. Visible increases
in melanogenesis were evident in stimulated cell pellets of cell
lines that had low basal melanin levels (Fig 6A1) compared with
high basal melanin levels (Fig 6A2).
Figure 2. Expression of b-END and l-opiate receptor in human skin EM. Normal human scalp cryosections (7 mm) were processed for double
immunolabeling as described in Materials and Methods. Expression of b-END was present throughout the epidermis and was more prominent in di¡eren-
tiated keratinocytes than in basal keratinocytes and was also marked in individual cells in the basal layer (A) (arrowheads). Identi¢cation of gp100-positive
EM located in the basal layer of the epidermis (B). b-END strongly colocalized (yellow) with gp100-positive EM (C) (arrowheads). m-Opiate receptor
expression was present throughout the epidermis and was stronger in the basal layer (D) (arrowheads). Identi¢cation of gp100-positive EM located in the
basal layer of the epidermis (E). m-Opiate receptor strongly colocalized (yellow) with gp100-positive EM (F) (arrowheads). Original magni¢cation  400.
Figure 3. The presence of l-opiate receptor and b-END in human skin EM. Normal human scalp cryosections (7 mm) were processed for double
immunolabeling as described in Materials and Methods. Expression of both m-opiate receptor (A) and b-END (B) was present in di¡erentiated keratinocytes
seen in yellow (arrow) when images (A) and (B) were merged. Strong colocalization of m-opiate receptor with b-END was also evident in individual cells
located in the basal layer of the epidermis (C) (arrowheads). Original magni¢cation  400.
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Evaluation of cell proliferation showed a signi¢cant increase
in EM number with b-END (10^8 M) stimulation after 72 h
(po0.001) (Fig 6B); however, the e¡ects of b-END on EM
proliferation were also variable (n¼ 8). The increase in cell
number ranged from 8.5%72.39 (SEM) to 29.5%72.39 with
an average increase of 14.9%72.39 above control unstimulated
levels. Based on the above in vitro results we propose that
b-END has signi¢cant melanogenic and mitogenic e¡ects on
EM.
b-END and l-opiate receptor colocalize on/in melanosomes
in cultured EM Lastly, we then addressed the issue of where b-
END and m-opiate receptor are located in melanocytes using
immunoelectron microscopy on cultured EM. Results revealed a
close association of b-END with melanosomes. b-END labeling
was con¢ned predominately, but not exclusively, to stage II and
III melanosomes, which represent early stages of active
melanogenesis (Fig 7A). m-Opiate receptor labeling was also
predominately present in premelanosomes but occasionally
associated with mature melanosomes (Fig 7B). Immunogold
labeling of m-opiate receptor was also located on the cell
membrane of melanocytes (data not shown). Thus, these results
indicate a speci¢c association of b-END and its receptor on/in
melanosomes in cultured EM.
DISCUSSION
Here we show for the ¢rst time that: (i) the b-END/m-opiate re-
ceptor system is prominently expressed in human EM in situ and
Figure 4. b-END and l-opiate receptor are expressed in cultured EM and EK. Cells were seeded into eight-well chamber slides and grown without
FBS or BPE for 48 h prior to immunostaining. Cells were ¢xed in ice cold methanol, blocked in 10% normal goat serum, and then incubated with the
primary antibodies against b-END and m-opiate receptor. Omission of the primary antibody served as a negative control.The expression of b-END (A) and
m-opiate receptor (B) was variable in cultured EM, expression was higher in di¡erentiated cells compared with undi¡erentiated cells and was strongest in the
perinuclear region of the cells (arrowheads). b-END immunoreactivity was also evident in granular structures in the nucleus (A) (arrow). Negative control
from which the primary antibody was omitted (C). Immunoreactivity for b-END in EK correlated positively with their di¡erentiation status and was
marked in more di¡erentiated keratinocytes than basal keratinocytes, stronger expression was con¢ned to the perinuclear region of the cell (D) (arrowheads).
Expression of m-opiate receptor was variable in EK and was stronger in basal keratinocytes compared with more di¡erentiated keratinocytes (E) (arrowheads).
Negative control from which the primary antibody was omitted (F). Original magni¢cation  150.
A) Control:72 hrs B) Stimulated:72 hrs
D) Stimulated:72 hrsC) Control:72 hrs 
Line 1
photo skin type III
Line 2
photo skin type V
Figure 5. Increased EM dendricity after 72 h b-END stimulation. EM cultures (passages 2^5) were established in basic ¢broblast growth factor/en-
dothelin-1 containing medium (n¼ 8). FBS and BPE were omitted from the culture 48 h prior to stimulation. A marked increase in cell dendricity was
seen 72 h after b-END stimulation in cells derived from photo skin type III (A,B) and photo skin type V (C,D).
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in vitro; (ii) the peptide and receptor are associated closely with
melanosomes; and (iii) the b-END/m-opiate receptor system is
functionally active in the regulation of melanocyte biology via
its ability upregulate melanocyte dendricity, proliferation, and
pigmentation. These new data strongly suggest that we need to
broaden our view of the regulation of human pigmentation from
its current MC-1R-centric state.
A role for several POMC peptides, especially a-MSH and
ACTH, in the regulation of EM melanogenesis (Hunt et al,
1994a, b, c; Suzuki et al, 1996;Wakamatsu et al, 1997) and hair fol-
licle pigmentation (Logan and Weatherhead, 1981; Burchill et al,
1986, 1989, 1993) via signaling through the MC-1R is well docu-
mented; however, a direct or even indirect role for b-END in
pigmentation biology remains controversial. Tantalizing clues
have been suggested, e.g., via the upregulation of b-END post-
UV radiation (Levins et al, 1983).We show here that the b-END/
m-opiate receptor system is fully expressed in human EM. Our
detection of mRNA expression for POMC in cultured adult
scalp EM and EK (Fig 1A) con¢rms recent work in neonatal
foreskin epidermis (Slominski et al, 1995; Schiller et al, 2001).
Although b-END can signal through both the m-opiate receptor
Figure 6. Increased EM melanogenesis and proliferation after 72 h
b-END stimulation. b-END-induced stimulation of melanogenesis was
determined by solubilization of cell pellets in 1 M sodium hydroxide. Mel-
anin content was determined spectrophotometrically at 475 nm. Results
were calculated as melanin content per cell and expressed as a percentage
increase in melanin content over control unstimulated cells (mean7SEM
of eight experiments). Statistical signi¢cance was assessed by Student’s
paired t test (nnnpo0.001) (A). A visible increase in melanogenesis was evi-
dent in pellets of the stimulated cells that contained low basal melanin le-
vels (A1) and was not appreciable in cells containing high basal melanin
levels (A2). For assessment of cell proliferation, cells were seeded at a den-
sity of 1  105 and cell counts were determined before and after 72 h b-
END stimulation. Results are expressed as a percentage increase in cell
number over control unstimulated levels (mean 7 SEM of eight experi-
ments). Statistical signi¢cance was assessed by Student’s paired t test
(nnnpo0.001) (B).
Figure 7. Ultrastructural localization of b-END and l-opiate recep-
tor in/on melanosomes in cultured EM. Immunoelectron microscopy
was performed on cultured EM using b-END and m-opiate receptor speci-
¢c antibodies labeled with secondary antibodies conjugated to 10 nm gold
particles. Melanosomes at di¡erent stages of maturation (I^IV) can be seen
by the increasing electron density of the organelles. b-END-labeled gold
particles were associated primarily with the outer membrane of stage II
and III melanosomes. The labeling was weaker in stage IV melanosomes
(A) (arrowheads). The frames indicate the origins of inserts (Ai) and (Aii).
m-Opiate receptor labeled gold particles were associated with premelano-
somes and occasionally with mature melanosomes (B) (arrowheads). The
frames indicate the origin of the inserts (Bi) and (Bii). No gold labeling
was seen in the negative control incubated with the gold-conjugated sec-
ondary antibody only (C). Original magni¢cation  20,000.
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and d-opiate receptor (Gilmore andWeiner, 1989), recent evidence
suggests that b-END binds speci¢cally to the m-opiate receptor in
EK (Bigliardi et al, 1998; Bigliardi-Qi et al, 2000) and these cells
do not express mRNA for either d-opiate receptor and k-opiate
receptor (Bigliardi et al, 1998). Using EK as a positive control for
m-opiate receptor expression, we demonstrated m-opiate receptor
mRNA expression also in cultured adult scalp EM (Fig 1B).
Reports on the expression of b-END at the protein level in
normal human epidermis are controversial. Whereas Slominski
et al (1993) showed b-END immunoreactivity in the basal layer
of scalp epidermis and also in follicular keratinocytes, others have
reported that b-END was expressed only in suprabasal keratino-
cytes of human epidermis (Nagahama et al, 1998). Using a speci¢c
anti-b-END monoclonal antibody, we report here b-END ex-
pression throughout the epidermis, but with increased immunor-
eactivity in the suprabasal layers; however, we also show high
expression of b-END in gp100-positive EM (Fig 2C). Examina-
tion of b-END expression was shown herein in normal human
scalp specimens derived from individuals of photo skin type
III^V (Fitzpatrick classi¢cation). Whether b-END expression in
human epidermis correlates with photo skin types is currently
under investigation, and this may explain the di¡erences between
our observations and the ¢ndings of others (Slominski et al, 1993;
Nagahama et al, 1998).
The expression of m-opiate receptor was recently reported
throughout the epidermis with higher expression in the basal
layer (Bigliardi et al, 1998), but this study did not identify m-opiate
receptor expression in basal melanocytes speci¢cally. m-Opiate re-
ceptor expression in EM was a prominent ¢nding in the current
study (Fig 2F). Thus, the presence of the b-END ligand and m-
opiate receptor system in both EM and EK provides the basis for
both autocrine and paracrine mechanisms to regulate melanocyte
behavior.
The novel and fundamental aspect of this study was its exam-
ination of a role for the b-END/m-opiate receptor system in the
modulation of melanocyte biology. Unlike its fellow POMC
peptides, a-MSH and ACTH, which stimulate melanogenesis,
dendricity, and proliferation in human EM via the MC-1R
(Hunt et al, 1994c; Abdel-Malek et al, 1995; Suzuki et al, 1996), a
regulatory role for b-END in EM biology has not hitherto been
demonstrated. Clues that such a role does indeed exist derive
from the observation that plasma b-END and b-LPH levels
increase after exposure to UV radiation (Levins et al, 1983; Belon,
1985), although it has also been suggested that b-END solely of
keratinocyte origin may be implicated in UV-induced melano-
genesis (Wintzen et al, 1996). In view of the present ¢ndings,
we can now con¢dently propose that b-END of melanocyte
origin may play a more pivotal role in these melanocyte-speci¢c
functions.
Autocrine control of melanocyte function was evident from a
positive correlation between b-END expression and melanocyte
di¡erentiation status (i.e., pigmentation and dendricity) (Fig 4A).
These results suggest that not only is b-END expressed by cul-
tured EM but it may also be involved in the modulation of mel-
anocyte di¡erentiation. Given that the expression of the m-opiate
receptor correlated positively with EM di¡erentiation (Fig 4B),
the level of m-opiate receptor expression may be upregulated by
its ligand b-END, as occurs with the binding of a-MSH/MC-1R
system (Chakraborty et al, 1995).
Whereas the expression of the receptor and ligand is highly
suggestive of a functional b-END/m-opiate receptor system in
EM, direct evidence is only obtainable from functional studies.
Thus, we also provide evidence that exogenously supplied
b-END can stimulate increased melanogenesis and proliferation
in EM cultures (Fig 6A,B). Importantly, these increases are of a
similar magnitude to those reported for a-MSH and ACTH sti-
mulation of EM (Hunt et al, 1994b,c), and so securely positions
b-END as having melanocortin activity despite not signaling
via MC-1R.
We have also demonstrated that b-END has potent dendrito-
genic e¡ects on EM. Thus, b-END-stimulated melanocytes pro-
duce more melanized pigment granules to facilitate more active
transfer of this melanin to recipient keratinocytes. In addition,
we have identi¢ed an association of b-END with melanosomes,
this ¢nding concurs with the recent identi¢cation of the full
POMC processing system in human melanosomes (Peters et al,
2000) and suggests that melanogenesis may be largely regulated
locally within this secretory granule. This scenario may include
the possibility of internalization of the receptor/ligand complex
into the melanosome and in this way facilitate intramelanosomal
regulation and subsequent melanogenesis.
A consistent, though confounding, feature of melanocortin
research is the donor variability in melanocyte responsiveness.
Similar to the situation with a-MSH and ACTH stimulation of
EM cultures (Hunt et al, 1994c, 1996), donor variability in b-END
responsiveness was also a feature of our study. It is now appre-
ciated that this interindividual variation for a-MSH and ACTH
re£ects di¡erences in the extent of peptide binding to the
MC-1R and its subsequent signaling activity. A similar situation
is likely to pertain to the m-opiate receptor.
It is now well documented that a-MSH and ACTH, acting via
the MC-1R, stimulates melanogenesis predominately by activat-
ing the adenylate cyclase/cyclic adenosine monophosphate second
messenger system (Busca and Ballotti, 2000). By contrast, b-END
exerts its biologic actions via the inhibition of this signaling path-
way. Protein kinase C-b dependent pathways, however, are in-
creasingly being implicated in the regulation of melanogenesis
(Park et al, 1993). In support of this emerging view, it has been
recently reported that topical application of bisindolylmaleimide,
a selective protein kinase C inhibitor, reduces skin pigmentation
in guinea pig skin in vivo.1 Our data support this view, and we
would like to propose that b-END/m-opiate receptor interaction
may signal via the protein kinase C b-isoform causing direct ac-
tivation of tyrosinase and stimulating melanogenesis. In this con-
text, it has been proposed that activation of protein kinase C
stimulates mouse tyrosinase promoter activity by a¡ecting the
amount or function of microphthalmia-associated transcription
factor expression (Mahalingam et al, 1997). It is possible that
b-END/m-opiate receptor signaling could operate on such sys-
tems at the level of gene transcription resulting in an increase
in tyrosinase expression and consequently the upregulation of
melanogenesis.
It will be important to determine whether b-END production
by EM is upregulated in response to stress, e.g., UV radiation,
pathology, etc. Indeed, patients with rheumatoid arthritis exhibit
high levels of b-END in synovial £uid (Denko et al, 1986). In
light of our current observations, we would like to speculate that
this local increase in b-END could also be responsible for the hy-
perpigmentation commonly observed in the skin of a¡ected
joints in these patients (Gedalia et al, 1989).
In conclusion, our ¢ndings propose an important new role
for b-END in the regulation of human skin pigmentation. In
contrast to the other melanocortins, this pigmentary response oc-
curs via an MC-1R independent mechanism, and so forces us to
broaden our current MC-1R-centric view of pigmentation con-
trol. Thus, these results should stimulate exciting new research
avenues into the fundamentals of the regulation of skin pigmen-
tation and o¡er insights into new therapies. It is also worth add-
ing here that these new data contribute to the evidence that
mammalian skin expresses a full range of regulatory elements of
the hypothalamic^pituitary^adrenal axis (Slominski and Worts-
man, 2000; Slominski et al, 2000a, 2001), and provides a further
developmental strand to the newly emerging ¢eld of cutaneous
neuroendocrinology.
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tion. J Invest Dermatol 119:337, 2002 (Abstr.)
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